RxSight, Inc. (NASDAQ:RXST) Director Jesse Anderson Corley Acquires 11,111 Shares

RxSight, Inc. (NASDAQ:RXST) Director Jesse Anderson Corley purchased 11,111 shares of the company’s stock in a transaction on Tuesday, November 12th. The shares were purchased at an average cost of $45.37 per share, with a total value of $504,106.07. Following the transaction, the director now directly owns 468,571 shares in the company, valued at $21,259,066.27. This trade represents a 2.43 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

RxSight Trading Down 1.1 %

RXST traded down $0.49 during trading hours on Thursday, hitting $44.16. The company’s stock had a trading volume of 1,078,070 shares, compared to its average volume of 489,598. The business’s 50-day moving average price is $50.48 and its 200-day moving average price is $53.33. RxSight, Inc. has a 12 month low of $26.85 and a 12 month high of $66.54. The stock has a market cap of $1.78 billion, a price-to-earnings ratio of -53.20 and a beta of 1.19.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Wells Fargo & Company decreased their price objective on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Oppenheimer reduced their price objective on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a research note on Tuesday, August 6th. Jefferies Financial Group started coverage on shares of RxSight in a report on Tuesday, October 29th. They set a “buy” rating and a $72.00 price target on the stock. Needham & Company LLC reissued a “buy” rating and issued a $66.00 price objective on shares of RxSight in a report on Friday, September 13th. Finally, Stifel Nicolaus lowered their price target on shares of RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, RxSight currently has an average rating of “Buy” and a consensus price target of $61.63.

Institutional Investors Weigh In On RxSight

Several large investors have recently bought and sold shares of the business. PDT Partners LLC bought a new stake in RxSight in the third quarter worth $896,000. Walleye Capital LLC increased its position in RxSight by 620.2% in the third quarter. Walleye Capital LLC now owns 129,687 shares of the company’s stock worth $6,410,000 after purchasing an additional 111,681 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in RxSight by 8.3% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 68,818 shares of the company’s stock worth $3,402,000 after buying an additional 5,266 shares during the period. MetLife Investment Management LLC boosted its stake in RxSight by 4.0% during the third quarter. MetLife Investment Management LLC now owns 20,525 shares of the company’s stock worth $1,015,000 after buying an additional 790 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its stake in RxSight by 1.9% during the third quarter. The Manufacturers Life Insurance Company now owns 20,911 shares of the company’s stock worth $1,034,000 after buying an additional 399 shares during the period. Institutional investors own 78.78% of the company’s stock.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.